We serve Chemical Name:(R)-(-)-2-Hexyl Isocyanate CAS:745783-77-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(R)-(-)-2-Hexyl Isocyanate
CAS.NO:745783-77-1
Synonyms:MFCD05664079;(2R)-2-isocyanatohexane
Molecular Formula:C7H13NO
Molecular Weight:127.18400
HS Code:2929109000
Physical and Chemical Properties:
Melting point:N/A
Boiling point:155.2ºC at 760 mmHg
Density:0.87g/cm3
Index of Refraction:1.44
PSA:29.43000
Exact Mass:127.10000
LogP:1.90090
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2206
Packing Group:III
Contact us for information like MFCD05664079 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2R)-2-isocyanatohexane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD05664079 Use and application,MFCD05664079 technical grade,usp/ep/jp grade.
Related News: Zynteglo is a one-time treatment for a blood disorder known as beta thalassaemia in patients 12 years and older who require regular blood transfusions. sodium,formaldehyde,2-hydroxybenzenesulfonate,4-(4-hydroxyphenyl)sulfonylphenol manufacturers OTL-101, by comparison, is designed to correct the problem by inserting working copies of the gene into a patient’s blood stem cells. 4-bromo-1-(4-fluorophenyl)pyrazolo[3,4-c]pyridine suppliers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit methyl 2,4-dimethylbenzoate vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit methyl 2,4-dimethylbenzoate vendor & factory.
